Christian Michael Glibert Sells 210,000 Shares of Nanovibronix (NASDAQ:FEED) Stock

Nanovibronix, Inc. (NASDAQ:FEEDGet Free Report) insider Christian Michael Glibert sold 210,000 shares of the stock in a transaction dated Monday, June 22nd. The stock was sold at an average price of $0.69, for a total transaction of $144,900.00. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.

Nanovibronix Stock Performance

Shares of FEED stock opened at $0.64 on Wednesday. The company has a 50 day moving average of $1.07. Nanovibronix, Inc. has a 52 week low of $0.62 and a 52 week high of $17.40. The firm has a market capitalization of $3.93 million, a P/E ratio of -0.07 and a beta of 1.52.

Nanovibronix (NASDAQ:FEEDGet Free Report) last posted its earnings results on Monday, May 18th. The company reported ($6.88) EPS for the quarter. The company had revenue of $0.65 million for the quarter. Nanovibronix had a negative net margin of 923.20% and a negative return on equity of 54.25%.

Analysts Set New Price Targets

FEED has been the topic of a number of recent research reports. Weiss Ratings reiterated a “sell (e+)” rating on shares of Nanovibronix in a research note on Friday, April 24th. Wall Street Zen raised shares of Nanovibronix from a “strong sell” rating to a “sell” rating in a report on Tuesday, April 28th. One analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company presently has a consensus rating of “Sell”.

Check Out Our Latest Report on Nanovibronix

Nanovibronix Company Profile

(Get Free Report)

Nanovibronix (NASDAQ: FEED) is a medical device company focused on the development and commercialization of non‑invasive therapeutic ultrasound technologies for clinical and consumer healthcare applications. The company’s product portfolio centers on wearable ultrasound devices designed to deliver low‑intensity acoustic energy to soft tissue with the objective of promoting wound healing and reducing pain. Nanovibronix positions its technology as an alternative or adjunct to conventional wound‑care and analgesic therapies, aiming to address chronic and acute conditions that are managed in both outpatient and home settings.

The company concentrates its commercial efforts on supplying hospitals, wound‑care clinics, long‑term care facilities and patients requiring home‑based therapies.

Featured Stories

Receive News & Ratings for Nanovibronix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nanovibronix and related companies with MarketBeat.com's FREE daily email newsletter.